A
research team led by Prof. Ben Ko Chi-bun, Associate Professor of the PolyU
Department of Applied Biology and Chemical Technology, has discovered the
critical mechanism of action of tetrandrine, a compound derived from Chinese
medicine Stephania tetrandra. Their work opens the door to innovative
treatments for viral infections and neurodegenerative disorders like
Alzheimer's and Parkinson's.
The findings have been published in Nature
Communications in a paper titled "Tetrandrine regulates
NAADP-mediated calcium signaling through a LIMP-2-dependent and
sphingosine-mediated mechanism."
Leveraging a specially designed
photoaffinity probe alongside other advanced tools to visualize tetrandrine's
cellular target, the team found that tetrandrine can target LIMP-2 to alter
lysosomal calcium release.
Tetrandrine, a compound isolated from
the root of a traditional Chinese medicine (TCM) Stephania tetrandra, has shown
promise in combating Ebola virus infection in previous studies. Its precise
mechanism of action, however, had remained unclear.
Researchers from The Hong Kong
Polytechnic University (PolyU) have discovered that tetrandrine works by
blocking the transport of sphingosine—a lipid molecule essential for cellular
signaling—and inhibiting the calcium channels. Their research has revealed the
critical mechanism of tetrandrine for the first time, opening new avenues for
drug discovery and disease treatment.
Tetrandrine is known for its potent
antiviral, anti-inflammatory and anti-cancer properties. It has been shown to
inhibit nicotinic acid adenine dinucleotide phosphate (NAADP)-mediated calcium
efflux, thereby suppressing the activity of the Ebola virus.
Scientists have long believed that tetrandrine elicits its pharmacological activity by directly blocking calcium channels and their release of calcium, which is a key regulator of cellular function and physiology including immune response, metabolism, brain and neuron functions, and viral replication.
They
discovered that, instead of directly targeting the calcium channels,
tetrandrine binds to the lysosomal integral membrane protein type-2 (LIMP-2) on
the lysosome—the metabolic hub of the cell—and blocks the discharge of
sphingosine from it.
The team further found that it is the
amount of cellular sphingosine that controls the activity of calcium channels: the less sphingosine released, the less calcium that
can enter the cells.
With this discovery, the researchers
propose that tetrandrine can be used to disrupt processes critical to the
survival and replication of viruses, such as Ebola and COVID-19, by targeting
LIMP-2 to alter lysosomal calcium release.
Importantly, these findings highlight
lysosome-related mechanisms as a new frontier for drug discovery, offering novel strategies for treating diseases
caused by calcium imbalance, including neurodegenerative disorders like
Alzheimer's and Parkinson's, as well as certain metastatic cancers.
Prof. Ko said, "This is the first
time a function of LIMP-2 in calcium signaling has been uncovered. From a cell
biology perspective, our study has revealed a completely new pathway for
NAADP-regulated calcium signaling, through LIMP-2 and sphingosine. From an
anti-viral treatment perspective, the study has identified LIMP-2 as a key
target of tetrandrine for the treatment of Ebola virus infection, with broader
applications in other antiviral therapies."
While illuminating tetrandrine's
biological mechanism, the research team has developed a technology platform that combines photoaffinity probe and
multi-omics analysis. This platform not only facilitates studies of natural
product biology, but also enables researchers to identify the molecular targets
of other natural compounds, particularly those derived from TCM.
By integrating modern analytical
techniques with TCM, it modernizes the use of natural products and expands
their therapeutic potential in the fight against the most challenging diseases,
supporting the development of innovative drugs.
The research redefines how natural compounds, such as tetrandrine, can be applied in modern therapeutic strategies.
No comments:
Post a Comment